My 19-year-old daughter required a treatment prescribed by her doctor. Even with my professional expertise, her doctor and I spent hours fighting to get her medication approved.

Specialty drugs: Abarca is mainly focused on ... particularly with the Big Three PBMs (CVS Caremark, Express Scripts and Optum Rx). The FTC has been investigating them, and several bills have ...

Walgreens Boots Alliance (WBA) finalized a $10 billion deal, worth as much as $23.7 billion, with Sycamore Partners to go ...

Prescription medication is counted before being placed into a bottle for customer pickup on Friday, Nov. 10, 2023. (Geoff ...

The firm has done a great job in bringing this balance down over the last three years but we do see some potential risk in the near term. Roughly 40% of debt is set to expire over the next three years ...

As of fiscal 2024, the firm held roughly $3.1 billion in cash and equivalents with a total debt balance of $9 billion. The firm has done a great job in bringing this balance down over the last three ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Walgreens (WBA) finalized an up to $27.3 billion deal to take itself private after four months of negotiations with Sycamore ...

The deal includes all elements of Walgreens, including VillageMD, which the company is winding down its stake in, and a specialty pharmacy ... UnitedHealth's Optum RX (UNH), CVS's Caremark ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...